Aspen's Commercial Pharmaceuticals sees promising growth amid restructuring efforts

ASPEN Pharmacare Holdings delivered a commendable performance in its Commercial Pharmaceuticals division, reporting a 10% increase in normalised earnings before interest, tax, depreciation, and amortisation (EBITDA) for the year 2025.

- EDWARD WEST

This growth is primarily attributed to robust advancements in their injectables, over-the-counter (OTC), and prescription drug segments. The division, which accounts for over 70% of group revenue, has experienced a resurgence bolstered by the rollout of Mounjaro in South Africa and the integration of an acquired product portfolio in Latin America.

Despite this positive trajectory, Aspen faced challenges stemming from the appreciation of the rand against its major trading currencies, which diluted overall earnings. The company also announced a dividend declaration of 211 cents per share, which represents a significant drop of 41.2% from the previous year’s 359 cents.

This decrease may come as a disappointment to investors as the firm navigates through competitive market conditions.

The firm is making strides in executing its generic semaglutide GLP-1 strategy, which includes sterile injectable products aimed at treating type 2 diabetes and obesity.